Caribou Biosciences, Inc.
CRBU
$1.96
$0.084.26%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 9.12M | 9.92M | 9.99M | 11.48M | 33.11M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 9.12M | 9.92M | 9.99M | 11.48M | 33.11M |
| Cost of Revenue | 62.73M | 63.42M | 63.30M | 64.71M | 63.47M |
| Gross Profit | -53.61M | -53.50M | -53.30M | -53.24M | -30.36M |
| SG&A Expenses | 36.57M | 37.65M | 42.56M | 41.79M | 45.56M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 159.48M | 168.35M | 171.51M | 172.16M | 174.69M |
| Operating Income | -150.35M | -158.43M | -161.52M | -160.68M | -141.58M |
| Income Before Tax | -164.27M | -147.87M | -149.11M | -147.93M | -123.25M |
| Income Tax Expenses | -9.00K | -9.00K | -9.00K | 193.00K | 193.00K |
| Earnings from Continuing Operations | -164.26 | -147.86 | -149.11 | -148.12 | -123.44 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -164.26M | -147.86M | -149.11M | -148.12M | -123.44M |
| EBIT | -150.35M | -158.43M | -161.52M | -160.68M | -141.58M |
| EBITDA | -145.66M | -154.05M | -157.59M | -157.20M | -137.69M |
| EPS Basic | -1.79 | -1.62 | -1.65 | -1.65 | -1.39 |
| Normalized Basic EPS | -1.00 | -0.98 | -1.00 | -1.00 | -0.87 |
| EPS Diluted | -1.79 | -1.62 | -1.65 | -1.65 | -1.39 |
| Normalized Diluted EPS | -1.00 | -0.98 | -1.00 | -1.00 | -0.87 |
| Average Basic Shares Outstanding | 367.33M | 364.64M | 361.26M | 358.53M | 351.86M |
| Average Diluted Shares Outstanding | 367.33M | 364.64M | 361.26M | 358.53M | 351.86M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |